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 Abstract 
Objectives Quantitative faecal immunochemical tests for haemoglobin (FIT) in 
colorectal cancer (CRC) screening pose challenges when colonoscopy is limited. For 
low positivity rates, high faecal haemoglobin concentration (f-Hb) cut-offs are 
required, but little is known about interval cancer (IC) proportions using FIT. We 
assessed IC proportions using an 80 μg Hb/g cut-off. 
Setting Two NHS Boards in the Scottish Bowel Screening Programme in which 
evaluation of FIT as a first-line test was performed. 
Methods f-Hb was estimated for 30893 participants aged 50-75 years: 753 
participants with f-Hb ≥ 80 μg Hb/g were referred for colonoscopy. IC, defined as 
CRC within two years of a negative result, were identified from the Scottish Cancer 
Registry. 
Results There were 31 IC and 30 screen-detected (SD) CRCs, an IC proportion of 
50.8%: 48.4%: for men and 53.3%: for women. CRC site distribution was similar 
between IC and SD, but IC were later stage (46.7% and 33.3%: Dukes’ stages C and 
D, respectively). Of 31 IC, 23 had f-Hb <10 μg Hb/g including six with undetectable f-
Hb. A f-Hb cut-off of 10 μg Hb/g would have raised the positivity rate from 2.4% to 
9.4%, increased colonoscopy requirement from 753 to 2147, and reduced the IC 
proportion to 38.3%. 
Conclusions The IC proportion was similar to that seen with guaiac-based FOBT. 
The later stage distribution of IC highlights the benefits of lower f-Hb cut-offs, but with 
19.4% of IC having undetectable f-Hb, some cancers would have been missed, even 
with drastic reduction in the f-Hb cut-off. 
 
  
 
Introduction 
 
Interval cancers (IC) are a significant issue in colorectal cancer (CRC) screening 
programmes. The Expert Working Group for Right-Sided Lesions and Interval 
Cancers, Colorectal Cancer Screening Committee, World Endoscopy Organization, 
recently recommended a standardised nomenclature for IC across all CRC screening 
modalities and colonoscopy surveillance, providing a definition of IC as: CRC 
diagnosed after a screening test or examination in which no cancer is detected and 
before the date of the next recommended examination.1 Minimising the number of 
undetected CRC is crucial to the success of CRC screening programmes in meeting 
their primary goal of reducing CRC mortality through early detection. 
 
Although randomised controlled trials (RCTs) have shown that guaiac faecal occult 
blood test (gFOBT) screening reduces CRC mortality,2 high proportions of all CRC 
diagnosed in the screened population that were IC, here referred to as the IC 
proportion, are commonly reported. In England3 and Denmark,4 IC proportions of 
51.3%  and 55.2% were found, and a large non-randomised trial in Burgundy 
calculated the IC proportion at 59.3%.5 Further studies from Denmark6 Scotland,7 and 
France8 have also provided evidence that IC consistently account for more than half 
of CRC detected in populations screened biennially with gFOBT. 
 
Previously published work has also identified some characteristics more associated 
with IC than gFOBT screen-detected (SD) CRC. Higher proportions of IC are found in 
women compared with SD CRC7,9,10  and significantly more IC have been 
demonstrated to arise in the right colon than SD CRC.7,9–15 Assuming advanced 
neoplasia was present at the time of the negative gFOBT, these findings suggest that 
 gFOBT may be more likely to detect pathology in men and in the left side of the 
colon. Furthermore, rectal cancers have been found to be more common amongst IC  
than SD CRC, 6–8 perhaps because tumour growth is faster for rectal cancer,16 or 
because the erythrocytes in any blood originating in the rectum have not been 
haemolysed and the still intact erythrocytes do not yield positive gFOBT or FIT. IC 
have also been associated with a worse prognosis, with larger, later stage tumours 
more frequently reported for IC compared with SD CRC. 6–8 
 
Countries worldwide are now introducing faecal immunochemical tests for 
haemoglobin (FIT) to replace gFOBT in CRC screening programmes, in view of their 
many advantages17 With numerous studies demonstrating FIT to be more sensitive 
tests than gFOBT, particularly for advanced adenoma detection,18 it is likely that FIT 
have the potential to reduce IC proportions. Moreover, quantitative FIT allow 
programme organisers to select a faecal haemoglobin concentration (f-Hb) cut-off 
most appropriate for their programme. However, this poses considerable challenges 
for countries with limited colonoscopy capacity. To secure low positivity rates that 
match colonoscopy capacity, high f-Hb cut-offs must be used, negating the improved 
sensitivity of FIT over gFOBT; this has been demonstrated by the results of an 
evaluation of quantitative FIT in Scotland at a cut-off f-Hb of 80 µg Hb/g faeces in 
which the positive predictive values (PPV) for advanced neoplasia were no better 
than with gFOBT.19 
 
Thus, it is important to establish the IC proportions associated with the use of FIT at 
a cut-off equivalent to gFOBT and if characteristics such as female sex and location 
in the proximal colon continue to show positive associations with IC.  However, data 
on IC proportions in population screening with FIT are lacking; these would provide 
essential insights into how quantitative FIT can be utilised in countries with limited 
colonoscopy capacity to minimise IC proportions and address the sex inequalities 
 that exist with gFOBT screening. In consequence, we assessed the consequences of 
FIT using a f-Hb cut-off of 80 µg Hb/g faeces (set to give ca. 2% positivity) in terms of 
IC within an established CRC screening programme. 
 
Methods 
 
The FIT as a first-line test evaluation has been described previously.19 From 01 July, 
2010, to 12 January, 2011, all eligible participants in the Scottish Bowel Screening 
Programme resident in NHS Tayside and NHS Ayrshire & Arran were sent a FIT kit 
pack containing an invitation letter, a booklet on bowel cancer, a thin card wallet with 
written and pictorial instructions for sample collection which contained a single faecal 
specimen collection device (Eiken Chemical Co. Ltd., Tokyo, Japan), a small zip-lock 
plastic bag with integral absorbent material, and a foil mailing pouch for device 
return. The population invited for screening were individuals aged 50–74 years. Both 
NHS Boards had offered screening previously, using a gFOBT/qualitative FIT two-tier 
reflex screening algorithm,20 but this was the first time that any participant had taken 
part in a quantitative FIT-based CRC screening programme. Those who sent an 
untestable FIT were sent another FIT kit pack. 
 
The characteristics of all returned samples were documented and the samples 
analysed for f-Hb using OC-Sensor Diana automated immunoturbidimetric analysers 
(Eiken). Analyses were carried out in the Scottish Bowel Screening Centre 
Laboratory by trained staff whose major function is to perform faecal test analyses; 
the Laboratory has a comprehensive total quality management system and is 
accredited to ISO15189 based standards by Clinical Pathology Accreditation (UK) 
Ltd. 
 
All participants with f-Hb < 80 µg Hb/g faeces were reported as negative and 
 informed by letter. All participants with f-Hb > 80 µg Hb/g faeces were reported as 
positive and contacted by letter, the general practitioner was notified, and the 
individual was referred to their NHS Board for colonoscopy. The f-Hb cut-off was 
chosen to give ca. 2% positivity, to mimic the positivity rate of the existing Screening 
Programme and match the available colonoscopy resource. Data for colonoscopy 
outcomes and any subsequent pathology were downloaded from the appropriate 
NHS Tayside and NHS Ayrshire & Arran clinical IT systems. Data on colonoscopy 
findings, including number, size, Dukes’ stage, and localisation of colorectal cancers 
and adenomas were collected. Right-sided location of neoplasia was defined as 
cancer detected in the region of the colon up to and including the splenic flexure, left-
sided as the region thereafter up to the recto-sigmoid junction, and rectal neoplasia 
as lesions located both in the recto-sigmoid junction and the rectum. 
 
Linkage with the Scottish Cancer Registry was performed to identify IC from the 
cohort of negative participants and to allow comparison of factors including f-Hb and 
gender distribution of CRC between the group with IC and those with SD CRC.  IC 
data was available for IC diagnosed up to 31 December 2012, meaning that the 
analysis included only negative participants with a result date up to 31 December 
2010 and participants with a later result date were excluded from the analysis. The 
linkage was completed using IBM SPSS version 21. CRC arising after a negative 
colonoscopy were referred to as “missed” cancers, and not IC in our cohort. 
 
Population weighted Scottish Index of Multiple Deprivation (SIMD) 2012 quintiles 
were used for analysis by deprivation.21 
 
MedCalc (MedCalc Software, Mariakerke, Belgium) statistical software was used for 
all calculations. The Mann-Whitney U test was used for comparison of median f-Hb 
between groups. Probability of p < 0.05 was considered significant. Logistic 
 regression analysis was performed to calculate odds ratios (OR) for IC amongst 
different demographic groups, adjusted for confounding variables. 
 
Results 
 
Over the six month screening period for which IC data was available, a total of 30893 
participants in the two NHS Boards responded to screening, with 30140 participants 
negative and 753 having a f-Hb above the 80 µg Hb/g cut-off concentration for 
positivity. 104 positive participants did not complete follow-up investigations due to 
either non-attendance, recently performed colonoscopy, or being deemed unfit for 
invasive procedures, and were excluded from further analysis. Of 649 participants 
completing investigations as a result of their positive FIT result, 30 had SD CRC. 31 
cases of IC were identified from follow-up of participants with a negative screening 
result to give an IC proportion of 50.8%.  Table 1 shows the characteristics 
associated with IC and SD. 
 
In men, 48.4% of all CRC were IC and, in women, 50.3% were IC. Median age in 
those with an IC was 68 years (interquartile range [IQR]: 63-72) compared with 67 
years (interquartile range: 61-72) for SD CRC cases. IC were diagnosed at a more 
advanced stage than SD CRC with 46.7% of IC being late stage (Dukes’ stage C or 
D) compared with 33.3% of SD CRC. 
 
Table 1. Characteristics of interval cancers and screen-detected colorectal cancer. 
 
    Interval cancers Screen-detected p-value 
    n % n %     
Total cases 31 50.8 30 49.2 1.00 
Sex       
 Men 15 48.4 16 51.6 
0.90 
 Women 16 53.3 14 46.7 
 Age quintile (years)*       
 50-54 0 0.0 4 100.0 
0.22 
 55-59 3 50.0 3 50.0 
 60-64 8 66.7 4 33.3 
 65-69 5 38.5 8 61.5 
 70-74 15 57.7 11 42.3 
Deprivation (SIMD)       
 1 (most deprived) 5 50.0 5 50.0 
0.95 
 2 4 66.7 2 33.3 
 3 5 35.7 9 64.3 
 4 9 60.0 6 40.0 
 5 (least deprived) 8 50.0 8 50.0 
Cancer site**       
 Right-sided 13 50.0 13 50.0 
0.99  Left-sided 5 50.0 5 50.0 
 Rectum 13 52.0 12 48.0 
Dukes' stage       
 A 6 42.9 8 57.1 
0.07 
 B 10 50.0 10 50.0 
 C 7 43.8 9 56.3 
 D 7 100.0 0 0.0 
  Not known 1 25.0 3 75.0   
 * age at time of invite. 
** right-sided CRC includes region up to and including the splenic flexure; left-sided includes 
descending and sigmoid colon; rectum includes recto-sigmoid junction and rectum. 
Table 2 shows median f-Hb and corresponding IQR at the time of screening in those 
who were subsequently found to have an IC, allowing comparison of f-Hb according 
to sex, CRC stage, site and time to diagnosis following screening. 
Table 2. Median f-Hb and interquartile range at time of negative screening test in 
those who had interval cancer. 
  n Median f-Hb IQR p-value 
   (µg Hb/g faeces)   
All  31 2.8 0.4-13.5  
Sex      
Men  15 12.6 0.1-12.9 
0.44 
Women  16 0.5 0.4-11.7 
Stage      
Total early  16 3.1 0.4-12.1 
0.47 
Total late  14 2.5 0.4-6.8 
Site      
Proximal  13 1.4 0.0-11.8 
0.39 
Distal  18 3.1 0.4-15.2 
Time to diagnosis     
 within 1 year 8 4.1 0.2-7.5 
0.79 
1-2 years  23 2.8 0.4-15.9 
 
The effect on positivity rate and IC proportion of lowering the f-Hb cut-off to various 
concentrations was assessed. Between cut-off concentrations of 80 µg Hb/g faeces 
and 10 µg Hb/g faeces, positivity rate would have increased steadily from 2.4% to 
9.4%, before escalating to 24.7% at 2 µg Hb/g faeces and 49.5% using a cut-off 
concentration of any detectable blood. Figure 1 shows the number of colonoscopies 
that would have been required at different f-Hb cut-offs alongside the associated 
proportions of IC and SD CRC. 
 
Figure 1. Effect of lowering the faecal haemoglobin (f-Hb) cut-off on proportions of 
interval cancer and screen-detected colorectal cancers (CRC) and number of 
colonoscopies required. 
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 Of the 31 IC cases, 23 had f-Hb < 10 µg Hb/g faeces at the time of their negative 
screening test, meaning that over a third of CRC cases would still have been missed 
if this f-Hb cut-off had been adopted. Furthermore, six of these 23 cases had 
undetectable f-Hb. With 51.8% of all participants in our evaluation having 
undetectable f-Hb,19 the proportion of IC arising in this group was compared with 
those with higher f-Hb and produced OR for IC, using those with no detectable f-Hb 
as the reference. OR were also calculated for men compared with women and for 
those between 60-69 years and over 70 years compared with those aged 50-59 
years. These results, along with OR also adjusted for all other factors investigated 
are displayed in Table 3.   
Table 3. Proportion of interval cancers by faecal haemoglobin (f-Hb), gender and age 
with adjusted odds ratios. 
   Adjusted odds ratio 
  % with interval cancer (95% CI) 
f-Hb (µg Hb/g faeces)   
 0 0.04 1.00 
 >0 0.17 3.84 (1.57 – 9.40) 
 >10 0.38 8.01 (2.73 – 23.56) 
 >20 0.44 8.74 (2.61 – 29.21) 
 >40 0.75 15.56 (3.76 – 64.33) 
 60-79.9 1.31 23.91 (4.73 – 120.81) 
    
Sex   
 Female 0.10 1.00 
 Male 0.11 1.01 (0.50 – 2.04) 
    
Age (years)   
 50-59 0.02 1.00 
 60-69 0.11 4.69 (1.33 – 16.47) 
 70+ 0.32 12.16 (3.50 – 42.26) 
 
 
Discussion 
 
Our results provide unique insights into IC proportions using FIT with a high f-Hb cut-
off (80 µg Hb/g faeces) in an established screening programme with limited 
 colonoscopy capacity and how these proportions could be influenced by varying the 
f-Hb cut-off. Our IC proportion was no different to the ca. 50% found using traditional 
gFOBT. 
 
A major strength of this study is that a large cohort of over 30000 completed FIT 
screening in the context of a fully rolled out operational screening programme, 
meaning that the implications on IC proportions of using a FIT at a high f-Hb cut-off 
concentration are what could be expected on nationwide implementation of FIT 
screening. Previous reports on this topic are very limited, therefore our results 
provide important evidence that FIT-based CRC screening programmes would 
benefit from use of low f-Hb cut-offs to gain lower IC proportions as well as higher 
sensitivity and detection of earlier stage disease, but at the cost of increased 
colonoscopy demand.22 This study also has limitations. The relatively small numbers 
of IC and SD CRC mean that statistical significance was not reached for differences 
between CRC categories for Dukes’ stage, for example. It is also important to bear in 
mind that the distributions of f-Hb are country specific.23 As a result, our findings may 
not necessarily be transferable. Screening programmes in other countries should 
perform their own analyses of IC proportions using FIT to determine the 
consequences of the use of different f-Hb cut-offs on IC. Moreover, our calculation of 
the yield of SD CRC at different f-Hb cut-offs is likely to be an underestimation. In 
addition to avoided IC, a lower f-Hb cut-off may also have led to detection of CRC 
that would arise as SD CRC the subsequent screening round as well as a small 
proportion of over-diagnosed cancers. Therefore, in reality the IC proportions would 
be lower than we have reported, although this is difficult to quantify. 
 
Our IC proportion of 50.8% at a cut-off concentration of 80 μg Hb/g was much higher 
than the overall 14.4% IC proportion found in Italy with a much lower f-Hb cut-off of 
20 µg Hb/g faeces,24 confirming that the use of a high f-Hb cut-off negates the 
 improved sensitivity for significant neoplasia offered by FIT over gFOBT and 
consequently increases the IC proportion.19 Previous findings that women have a 
higher IC proportion than men, at least when a high f-Hb cut-off is used, are 
supported to some extent. In attempting to explain this, we analysed characteristics 
associated with CRC between the sexes. In contrast to results of previous studies 
investigating IC in gFOBT screening programmes, an association with location in the 
proximal colon for IC in women was lacking, with just a quarter of cases in women 
located from the caecum up to and including the splenic flexure, whereas most IC in 
men were right-sided. However, the relatively small numbers of IC and SD CRC 
detected in this study make this lack of association unreliable, and indeed, the 
relationships between IC proportions and sex and age did not reach statistical 
significance although, reassuringly, the trends were as expected. 
 
The more advanced stage distribution of IC highlights the need for measures to be 
taken to improve CRC detection with screening. Lowering the f-Hb cut-off would be 
an obvious solution, but the resultant increase in colonoscopy demand may not be 
sustainable given the available resources. For example, in our cohort, halving the f-
Hb cut-off to 40 µg Hb/g faeces would reduce the IC proportion from 50.8% to only 
45.9%, but with a significant 58.6% increase in the number of colonoscopies 
required. Small gains in sensitivity would come at the cost of significant losses in 
specificity and PPV. This problem could be counteracted by screening at a low f-Hb 
cut-off, but with a longer interval between screening rounds than the two years 
currently implemented, and investigating the impact of such a strategy on IC 
proportions is an important area for future research. In addition, given the important 
effects of age and gender on IC proportions seen in previous studies and supported 
here, exploring stratified f-Hb cut-offs based on these variables is warranted. 
 
Although participants who had an undetectable f-Hb accounted for over half of the 
 screened population, the proportion of IC in this group was relatively small, over 30 
times lower than the proportion of IC identified in those with f-Hb in the range 60.0 – 
79.9 µg Hb/g faeces, who constituted just 0.5% of the cohort. Adjusted OR 
demonstrated increasing risk of IC with increasing f-Hb and perhaps indicate a need 
for participants with elevated f-Hb to be offered more regular screening. As we have 
suggested previously, since men and women have different f-Hb as do older 
participants compared to younger,22,25 our results support the inclusion of  numerical 
data for f-Hb in risk-scoring models for population CRC screening such as recently 
advocated.26 With IC being associated with a worse prognosis, it appears that 
women and older participants may be disadvantaged by the use of a single f-Hb cut-
off for all and we therefore consider that better individualised use of FIT in CRC 
screening is required. However, further work is required to determine specific 
performance characteristics of FIT in subgroups at different f-Hb cut-off 
concentrations.  IC proportion alone is not sufficient to address inequalities; for 
instance CRC incidence rates are lower among women than men meaning that the 
residual risk of IC diagnosis following a negative screening result will also be lower in 
women than in men. Therefore, the selection of the appropriate f-Hb cut-off 
concentration is complex and other factors such as PPV are an important 
consideration in a setting limited by endoscopic resources. 
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